Skip to search formSkip to main contentSkip to account menu

AZD5438

National Institutes of Health

Related topics

Related topics

3 relations
AZD2171

Broader (2)

ImidazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl‐xL silenced cells
In the present study, we investigated the effect of CDK inhibitors (ribociclib, palbociclib, seliciclib, AZD5438, and dinaciclib… 
2015
2015
MP55-11 SYNTHETIC LETHAL METABOLIC TARGETING OF CELLULAR SENESCENCE IN PROSTATE CANCER WITH METFORMIN
2015
2015
MP55-12 THE PROTON-ASSISTED AMINO ACID TRANSPORTER 4 (PAT4/SLC36A4) IS UP-REGULATED IN PROSTATE CANCER
2009
2009
AZD 5438 , a potent oral inhibitor of cyclin-dependent kinases 1 , 2 , and 9 , leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Deregulation of the cell cycle has long been recognized as an essential driver of tumorigenesis, and agents that selectively… 
2007
2007
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood…
PurposeAZD5438 is a novel, orally bioavailable, cyclin-dependent kinase (CDK) inhibitor demonstrating preclinical pharmacodynamic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)